Evidence-based clinical practice guidelines for inflammatory bowel disease
2018 · Journal of Gastroenterology · 684 citations
https://doi.org/10.1007/s00535-018-1439-1
H
Hiroshi Nakase
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
716
Papers
16.3K
Citations
62
h-index
257
i10-index
Hiroshi Nakase is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Helicobacter pylori-related gastroenterology studies. The author has an h-index of 62, co-authored 609 publications.
ORCID: 0000-0003-2848-6586Papers by this author
worksUpadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2022 · The Lancet · 544 citations
https://doi.org/10.1016/s0140-6736(22)00581-5
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 · New England Journal of Medicine · 373 citations
https://doi.org/10.1056/nejmoa2212728
Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study
2009 · Gastrointestinal Endoscopy · 131 citations
https://doi.org/10.1016/j.gie.2008.12.242
The role of Hes genes in intestinal development, homeostasis and tumor formation
2012 · Development · 130 citations
https://doi.org/10.1242/dev.069070
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
2018 · Journal of Gastroenterology · 123 citations
https://doi.org/10.1007/s00535-018-1486-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat